FIGO 2023 staging for endometrial cancer, when, if it is not now?

Xavier Matias-Guiu; Sigurd Lax; Maria Rosaria Raspollini; Jose Palacios; Wenxin Zheng; Congrong Liu; Louise de Brot; Leonardo Lordello; David Hardisson; David Gaffney; David Mutch; Giovanni Scambia; Carien L. Creutzberg; Christina Fotopoulou; Jonathan S. Berek; Nicole Concin

doi:10.1016/j.ejca.2024.115115

FIGO 2023 staging for endometrial cancer, when, if it is not now?

Xavier Matias-Guiu, Sigurd Lax, Maria Rosaria Raspollini, Jose Palacios, Wenxin Zheng, Congrong Liu, Louise de Brot, Leonardo Lordello, David Hardisson, David Gaffney, David Mutch, Giovanni Scambia, Carien L. Creutzberg, Christina Fotopoulou, Jonathan S. Berek, Nicole Concin

Research output: Contribution to journal › Review article › peer-review

1 Scopus citations

Abstract

Incorporation of pathological and (not mandatory) molecular features into the new FIGO 2023 staging system has generated some controversy. Several validations have been published recently that demonstrated the higher prognostic precision of FIGO 2023 compared to the previous FIGO 2009 scheme. In the present article, the authors want to respond to some concerns that were raised by some pathologists and clinicians.

Original language	English
Article number	115115
Journal	European Journal of Cancer
Volume	213
DOIs	https://doi.org/10.1016/j.ejca.2024.115115
State	Published - Dec 2024

Keywords

Endometrial cancer
Pathology
Prognosis
Stage

Access to Document

10.1016/j.ejca.2024.115115

Cite this

Matias-Guiu, X., Lax, S., Raspollini, M. R., Palacios, J., Zheng, W., Liu, C., de Brot, L., Lordello, L., Hardisson, D., Gaffney, D., Mutch, D., Scambia, G., Creutzberg, C. L., Fotopoulou, C., Berek, J. S., & Concin, N. (2024). FIGO 2023 staging for endometrial cancer, when, if it is not now? European Journal of Cancer, 213, Article 115115. https://doi.org/10.1016/j.ejca.2024.115115

@article{4e19ad7f13f046e89696947cacbcde89,

title = "FIGO 2023 staging for endometrial cancer, when, if it is not now?",

abstract = "Incorporation of pathological and (not mandatory) molecular features into the new FIGO 2023 staging system has generated some controversy. Several validations have been published recently that demonstrated the higher prognostic precision of FIGO 2023 compared to the previous FIGO 2009 scheme. In the present article, the authors want to respond to some concerns that were raised by some pathologists and clinicians.",

keywords = "Endometrial cancer, Pathology, Prognosis, Stage",

author = "Xavier Matias-Guiu and Sigurd Lax and Raspollini, {Maria Rosaria} and Jose Palacios and Wenxin Zheng and Congrong Liu and {de Brot}, Louise and Leonardo Lordello and David Hardisson and David Gaffney and David Mutch and Giovanni Scambia and Creutzberg, {Carien L.} and Christina Fotopoulou and Berek, {Jonathan S.} and Nicole Concin",

note = "Publisher Copyright: {\textcopyright} 2024 Elsevier Ltd",

year = "2024",

month = dec,

doi = "10.1016/j.ejca.2024.115115",

language = "English",

volume = "213",